<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806259</url>
  </required_header>
  <id_info>
    <org_study_id>KBCtrial</org_study_id>
    <nct_id>NCT01806259</nct_id>
  </id_info>
  <brief_title>Ketorolac in Breast Cancer Surgery</brief_title>
  <acronym>KBCt</acronym>
  <official_title>Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Do the use of Ketorolac in one intravenous injection at the moment of the operative incision
      reduce the number of recurrence in patient with advanced breast cancer without inflammation
      signs.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ketorolac on recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>2 years for the primary analysis + 3 additional years for secondary analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of ketolorac in pain control</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ketorolac on inflammatory and growth factors</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of inflammatory markers (NLR, cytokines, angiogenic profile)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>effect of ketorolac on overall survival</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Curative Breast Cancer Surgery</condition>
  <condition>Inflammatory Positive/Negative Status</condition>
  <condition>Pre Surgical Incision Administration</condition>
  <arm_group>
    <arm_group_label>ketorolac 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug to be compared with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9% 3mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac 30 mg IV</intervention_name>
    <arm_group_label>ketorolac 30 mg</arm_group_label>
    <arm_group_label>NaCl 0.9% 3mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed Consent age : 18-85 years weight: 50-100 kg Neutrophils / Lymphocytes
        ratio &gt;4 and/or &quot;triple negative&quot; histological status and/or Positive lymph nodes

        Exclusion Criteria:

        Previous cancer (behalf of basocellular skin cancer and in situ uterine cervix cancer) Non
        compliance or refusal of the protocol Positive Pregnancy test Childbearing or breastfeeding
        mothers Contra-indication for NSAIDs NSAIDs intake in the 5 days before randomisation
        NSAIDs use planned in the 30 days after randomisation Non curative surgery (T4 or M1 tumor
        classification )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Forget, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.anesthesia-analgesia.org</url>
  </link>
  <reference>
    <citation>Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C, De Kock M. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010 Jun 1;110(6):1630-5. doi: 10.1213/ANE.0b013e3181d2ad07. Epub 2010 Apr 30.</citation>
    <PMID>20435950</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Forget Patrice</investigator_full_name>
    <investigator_title>Docteur</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

